AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-216-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.15 million
Profitability
Miscellaneous
Employees61
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) issued its quarterly earnings data on Monday, August, 5th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The specialty pharmaceutical company had revenue of $0.94 million for the quarter, compared to analysts' expectations of $1.55 million. View AcelRx Pharmaceuticals' Earnings History.
When is AcelRx Pharmaceuticals' next earnings date?
What price target have analysts set for ACRX?
8 equities research analysts have issued 1 year target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $6.50 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $8.07 in the next year. This suggests a possible upside of 265.8% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.
What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.
What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?
Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (7/9/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019)
Has AcelRx Pharmaceuticals been receiving favorable news coverage?
News coverage about ACRX stock has been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for AcelRx Pharmaceuticals.
Are investors shorting AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals saw a drop in short interest in September. As of September 30th, there was short interest totalling 13,470,000 shares, a drop of 5.1% from the August 30th total of 14,200,000 shares. Based on an average daily volume of 913,500 shares, the days-to-cover ratio is currently 14.7 days. Approximately 19.1% of the company's stock are short sold. View AcelRx Pharmaceuticals' Current Options Chain.
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include Wave Life Sciences (WVE), ZIOPHARM Oncology (ZIOP), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Vectura Group (VEGPF), Cytokinetics (CYTK), Advanz Pharma (CXRXF), Karyopharm Therapeutics (KPTI), Axsome Therapeutics (AXSM), Kura Oncology (KURA), Revance Therapeutics (RVNC), NextCure (NXTC), Homology Medicines (FIXX), Rocket Pharmaceuticals (RCKT) and Arvinas (ARVN).
What other stocks do shareholders of AcelRx Pharmaceuticals own?
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Mr. Vincent J. Angotti, CEO & Director (Age 51)
- Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
- Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $2.21.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $175.28 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.View Additional Information About AcelRx Pharmaceuticals.
What is AcelRx Pharmaceuticals' official website?
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
